Company intelligence / Profile preview

GlobalBio, Inc.

Cambridge, Massachusetts, United Statesglobalbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GlobalBio has developed a panel of anti-PD‑1 antibodies with diverse binding/functional profiles. Two candidates are entering preclinical development as immune checkpoint inhibitors for cancer therapy. The company leverages proprietary semisynthetic libraries and advanced computational methods to engineer improved therapeutic antibodies.

Therapeutic areas: OncologyOther
Modalities: Monoclonal antibodies (mAbs)Antibody-based therapiesRecombinant proteins
Industry: Biotech

Partnerships

Antiverse Ltd. – collaboration on AI-driven antibody discovery targeting immune checkpoints in cancer therapy.

Beyond the preview

Go deeper on GlobalBio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlobalBio, Inc..

Explore the full profile